Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Leases (2019 - 2026)

Anika Therapeutics has reported Current Leases over the past 8 years, most recently at $1.9 million for Q1 2026.

  • Quarterly Current Leases rose 3.63% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2026, up 3.63% year-over-year, with the annual reading at $2.1 million for FY2025, 6.99% up from the prior year.
  • Current Leases was $1.9 million for Q1 2026 at Anika Therapeutics, down from $2.1 million in the prior quarter.
  • Over five years, Current Leases peaked at $2.3 million in Q3 2024 and troughed at $122000.0 in Q1 2022.
  • The 5-year median for Current Leases is $1.9 million (2026), against an average of $1.9 million.
  • Year-over-year, Current Leases surged 1625.41% in 2023 and then fell 24.74% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.1 million in 2022, then dropped by 11.87% to $1.8 million in 2023, then rose by 4.98% to $1.9 million in 2024, then grew by 6.99% to $2.1 million in 2025, then fell by 5.36% to $1.9 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Current Leases are $1.9 million (Q1 2026), $2.1 million (Q4 2025), and $1.7 million (Q3 2025).